Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

The Histone Deacetylase 1 and 2 (HDAC1/2) Inhibitor ACY-957: Impact of Dosing Schedule on Pharmacokinetics (PK), Pharmacodynamics (PD), Hematopoietic Toxicity, and Gamma Globin (HBG, ɣ) Expression in Monkey

Apurva Chonkar, MS, Matthew Jarpe, PhD, Kailash Bhol, PhD, Simon S Jones, PhD, Jeffrey R Shearstone, PhD

Blood (2016) 128 (22): 323.

https://doi.org/10.1182/blood.V128.22.323.323

Published: 2016

Journal Articles

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

Blood (2016) 128 (22): 3307.

https://doi.org/10.1182/blood.V128.22.3307.3307

Published: 2016

Journal Articles

Combinatorial Effect of HDAC6i and Ibrutinib Therapy in CLL Murine Model

Kamira Karen Maharaj, BS, John J. Powers, B.S., Susan Deng, BS, Alex Achille, BS, Mibel Pabon-Saldana, Renee Fonseca, Steven N Quayle, Simon S Jones, PhD, Eva Sahakian, PhD, Javier Pinilla-Ibarz, MD PhD

Blood (2016) 128 (22): 2035.

https://doi.org/10.1182/blood.V128.22.2035.2035

Published: 2016

Journal Articles

ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)

Ruben Niesvizky, MD, Paul G. Richardson, MD, Nashat Y. Gabrail, MD, Sumit Madan, MD, Andrew J. Yee, MD, Steven N Quayle, PhD, Ingrid Almeciga-Pinto, PhD, Simon S Jones, PhD, Lee Houston, Denise Hayes, John Van Duzer, PhD, Catherine Wheeler, MD, Nikolaus S. Trede, MD PhD, Noopur S. Raje, MD

Blood (2015) 126 (23): 3040.

https://doi.org/10.1182/blood.V126.23.3040.3040

Published: 2015

Journal Articles

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)

Noopur S. Raje, MD, William Bensinger, MD, Craig E. Cole, MD, Sagar Lonial, MD, Sundar Jagannath, MD, Carlos E. Arce-Lara, MD, Jason Valent, MD, Ashley E Rosko, MD, Wael A. Harb, MD, Irwindeep Sandhu, MD, Nizar J Bahlis, MD, Donna Reece, Evangelos Terpos, MD, Jeffrey Supko, PhD, David Tamang, PhD, Simon S Jones, PhD, Catherine Wheeler, MD, Robert J Markelewicz, Jr., MD, Paul G. Richardson

Blood (2015) 126 (23): 4228.

https://doi.org/10.1182/blood.V126.23.4228.4228

Published: 2015

Journal Articles

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study)

Dan T. Vogl, MD, Noopur S. Raje, MD, Sundar Jagannath, MD, Paul G. Richardson, MD, Parameswaran Hari, MD MRCP, MS, Robert Z. Orlowski, PhD, MD, Jeffrey Supko, PhD, David Tamang, PhD, Simon S Jones, PhD, Catherine Wheeler, MD, Robert J Markelewicz, Jr., MD, Sagar Lonial, MD

Blood (2015) 126 (23): 1827.

https://doi.org/10.1182/blood.V126.23.1827.1827

Published: 2015

Journal Articles

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study)

Andrew J. Yee, MD, William Bensinger, MD, Peter M. Voorhees, MD, Jesus G. Berdeja, MD, Paul G. Richardson, MD, Jeffrey Supko, PhD, David Tamang, PhD, Simon S Jones, PhD, Catherine Wheeler, MD, Robert J Markelewicz, Jr., MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 3055.

https://doi.org/10.1182/blood.V126.23.3055.3055

Published: 2015

Journal Articles

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma

Jennifer E Amengual, MD, Lichtenstein Renee, Celeste Rojas, Kelly Zullo, MS, Maximilian Lombardo, Emily Lichtenstein, RN, Ellen Neylon, NP, Changchun Deng, MD PhD, Ahmed Sawas, MD, Bijal D Shah, Catherine Wheeler, MD, Simon S Jones, PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 1280.

https://doi.org/10.1182/blood.V126.23.1280.1280

Published: 2015

Journal Articles

The Histone Deacetylase 1 and 2 (HDAC1/2) Inhibitor ACY-957 Increases Epsilon (HbE) and Gamma (HbG) Globin mRNA in the Peripheral Blood of Non-Anemic Rats and Monkeys

Jeffrey R Shearstone, PhD, Apurva Chonkar, MS, Kailash Bhol, PhD, Simon S Jones, PhD, Matt Jarpe, PhD

Blood (2015) 126 (23): 3378.

https://doi.org/10.1182/blood.V126.23.3378.3378

Published: 2015

Journal Articles

Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL)

John J. Powers, B.S., Kamira K. Maharaj, B.S., Eva Sahakian, PhD, Limin Xing, PhD, Patricio PerezVillarroel, BS, Tessa Knox, MS, Steven Quayle, Simon S Jones, PhD, Alejandro Villagra, PhD, Eduardo M. Sotomayor, MD, Javier Pinilla-Ibarz, MD PhD

Blood (2014) 124 (21): 3311.

https://doi.org/10.1182/blood.V124.21.3311.3311

Published: 2014

Journal Articles

Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

Dan T. Vogl, Noopur Raje, MD, Parameswaran Hari, MBBS, MD MRCP, Simon S Jones, PhD, Jeffrey G Supko, PhD, Gina Leone, RN, Catherine Wheeler, MD, Robert Z. Orlowski, PhD MD, Paul G. Richardson, Sagar Lonial, MD, David Tamang, PhD, Sundar Jagannath, MD

Blood (2014) 124 (21): 4764.

https://doi.org/10.1182/blood.V124.21.4764.4764

Published: 2014

Journal Articles

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma

Andrew J Yee, MD, Peter M. Voorhees, MD, William Bensinger, Jesus G. Berdeja, MD, Jeffrey G Supko, PhD, Paul G. Richardson, David Tamang, PhD, Simon S Jones, PhD, Gretchen Patrick, Catherine Wheeler, MD, Noopur Raje, MD

Blood (2014) 124 (21): 4772.

https://doi.org/10.1182/blood.V124.21.4772.4772

Published: 2014

Journal Articles

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Fengdong Cheng, MD, Bing Xia, MD, Eva Sahakian, PhD, Tint Lwin, MD PhD, Hongwei Wang, MD, Limin Xing, MD, Bijal D. Shah, MD, Patricio PerezVillarroel, BS, Maritza LienlafMoreno, BS, Yizhuo Zhang, MD, Steven N Quayle, PhD, Simon S Jones, PhD, Javier Pinilla-Ibarz, MD PhD, Alejandro Villagra, PhD, Eduardo M. Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2014) 124 (21): 5397.

https://doi.org/10.1182/blood.V124.21.5397.5397

Published: 2014

Journal Articles

Inhibition Of HDAC6 In Combination With Targeted Agents Results In Broad Synergistic Decreases In Viability In Non-Hodgkin’s Lymphoma (NHL) Cells

Steven N Quayle, PhD, David Tamang, PhD, Min Yang, PhD, Simon S Jones, PhD

Blood (2013) 122 (21): 3071.

https://doi.org/10.1182/blood.V122.21.3071.3071

Published: 2013

Journal Articles

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma

Yuko Mishima, Loredana Santo, Diana D. Cirstea, Homare Eda, Neeharika Nemani, Shirin Arastu-Kapur, Ph.D, Christopher J. Kirk, Ph.D, Simon S Jones, PhD, Raje Noopur, MD

Blood (2013) 122 (21): 4431.

https://doi.org/10.1182/blood.V122.21.4431.4431

Published: 2013

Journal Articles

Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models

Allison J Berger, PhD, Bret Bannerman, Steven N Quayle, PhD, Jie Yu, Khristofer Garcia, Jeffrey Ciavarri, PhD, David Tamang, PhD, Min Yang, PhD, Simon S Jones, PhD

Blood (2013) 122 (21): 4437.

https://doi.org/10.1182/blood.V122.21.4437.4437

Published: 2013

Journal Articles

ACY-1215, a First-In-Class Selective Inhibitor Of HDAC6, Demonstrates Significant Synergy With Immunomodulatory Drugs (IMiDs) In Preclinical Models Of Multiple Myeloma (MM)

Steven N Quayle, PhD, Simon S Jones, PhD

Blood (2013) 122 (21): 1952.

https://doi.org/10.1182/blood.V122.21.1952.1952

Published: 2013

Journal Articles

Tubulin Hyper-Acetylation In Blood Lymphocytes: Pharmacodynamic (PD) Biomarker For The Selective Histone Deacetylase (HDAC) 6 Inhibitor ACY-1215 In Multiple Myeloma (MM) Patients

David Tamang, PhD, Simon S Jones, PhD, Min Yang, PhD, Jeff Supko

Blood (2013) 122 (21): 3219.

https://doi.org/10.1182/blood.V122.21.3219.3219

Published: 2013

Journal Articles

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b Trial

Andrew Yee, Peter Vorhees, MD, William I. Bensinger, MD, Jesus Berdeja, MD, Jeffrey G Supko, PhD, Paul G. Richardson, MD, Simon S Jones, PhD, Gretchen Patrick, Catherine Wheeler, MD, Noopur Raje, MD

Blood (2013) 122 (21): 3190.

https://doi.org/10.1182/blood.V122.21.3190.3190

Published: 2013

Journal Articles

Discovery Histone Deacetylase (HDAC)6 Specific Proteomic Biomarkers In Multiple Myeloma (MM) Using Stable Isotope Labeling By Amino Acids In Cell Culture (SILAC)

Min Yang, PhD, David Tamang, PhD, Simon S Jones, PhD, Zhongyi Cheng, Ph.D., Gungwei Chirn, Ph.D

Blood (2013) 122 (21): 1909.

https://doi.org/10.1182/blood.V122.21.1909.1909

Published: 2013

NARROW

The Histone Deacetylase 1 and 2 (HDAC1/2) Inhibitor ACY-957: Impact of Dosing Schedule on Pharmacokinetics (PK), Pharmacodynamics (PD), Hematopoietic Toxicity, and Gamma Globin (HBG, ɣ) Expression in Monkey

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

Combinatorial Effect of HDAC6i and Ibrutinib Therapy in CLL Murine Model

ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study)

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study)

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma

The Histone Deacetylase 1 and 2 (HDAC1/2) Inhibitor ACY-957 Increases Epsilon (HbE) and Gamma (HbG) Globin mRNA in the Peripheral Blood of Non-Anemic Rats and Monkeys

Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL)

Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Inhibition Of HDAC6 In Combination With Targeted Agents Results In Broad Synergistic Decreases In Viability In Non-Hodgkin’s Lymphoma (NHL) Cells

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma

Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models

ACY-1215, a First-In-Class Selective Inhibitor Of HDAC6, Demonstrates Significant Synergy With Immunomodulatory Drugs (IMiDs) In Preclinical Models Of Multiple Myeloma (MM)

Tubulin Hyper-Acetylation In Blood Lymphocytes: Pharmacodynamic (PD) Biomarker For The Selective Histone Deacetylase (HDAC) 6 Inhibitor ACY-1215 In Multiple Myeloma (MM) Patients

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b Trial

Discovery Histone Deacetylase (HDAC)6 Specific Proteomic Biomarkers In Multiple Myeloma (MM) Using Stable Isotope Labeling By Amino Acids In Cell Culture (SILAC)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only